Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1:434:133329.
doi: 10.1016/j.ijcard.2025.133329. Epub 2025 Apr 29.

The plasma proteome is linked to echocardiographic parameters and stages of diastolic dysfunction, across the ejection fraction spectrum

Sabrina Abou Kamar  1 , Anne-Mar van Ommen  2 , Elisa Dal Canto  3 , Gideon Valstar  2 , K Martijn Akkerhuis  4 , Maarten J Cramer  5 , Victor Umans  6 , Frans Rutten  7 , Arco J Teske  5 , Roxana Menken  8 , Marcel L Geleijnse  4 , Leonard Hofstra  9 , Marianne C Verhaar  10 , Rudolf A de Boer  4 , Eric Boersma  4 , Folkert W Asselbergs  11 , Bas M van Dalen  1 , Hester M den Ruijter  12 , Isabella Kardys  13
Affiliations
Free article

The plasma proteome is linked to echocardiographic parameters and stages of diastolic dysfunction, across the ejection fraction spectrum

Sabrina Abou Kamar et al. Int J Cardiol. .
Free article

Abstract

Introduction: This study investigates the interplay between the circulating plasma proteome and echocardiographic parameters in patients across the spectrum of heart failure (HF) (ranging from patients at risk of/with preserved (HFpEF) to reduced (HFrEF) ejection fraction).

Methods: Data from two cohort studies, HELPFul and Bio-SHiFT, were analyzed. We measured 4210 circulating plasma proteins in a total of 750 patients using SomaScan® proteomics. Echocardiographic parameters in both studies included left ventricular ejection fraction (LVEF) and the ratio of the peak early left ventricular (LV) filling velocity and early diastolic mitral annular velocity (E/e'). In further analyses, we classified patients in left ventricular diastolic dysfunction (LVDD) groups according to the prevailing guidelines.

Results: Out of the 4210 plasma proteins, 21 proteins were significantly associated with E/e' in patients at risk of/with HFpEF, whereas 9 proteins were associated with LVEF. Approximately 43 % (n = 1822) of the proteins showed significant interactions between E/e' and HF subtype. All of these proteins showed weaker associations with E/e' in patients at risk of/with HFpEF compared to the ones with HFrEF. These proteins were related to the extracellular matrix, cellular processes, insulin-like growth factor (IGF) transport, metabolic and catabolic processes. Furthermore, comparisons between LVDD groups and those with normal diastolic function identified 40 proteins associated with grade 2 (top 5: Cystatin C, TMEDA, NT-proBNP, GDF-15 and PXDN) and 198 with grade 3 LVDD (top 5: NT-proBNP, Cystatin C, PXDN, RNasa1, and Factor D).

Conclusion: In patients at risk of/with HFpEF, biological processes and pathways showed weaker associations with E/e' compared to patients with HFrEF. Varying pathways identified through proteomics were associated with deterioration of LVDD across the ejection fraction spectrum. Our results are in line with the mechanistic frameworks currently thought to underlie the various types of HF.

Keywords: Diastolic dysfunction; E/e’; Echocardiography; Heart failure; Proteomics.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The institution of Dr. De Boer has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Cardior Pharmaceuticals GmbH, NovoNordisk, and Roche; Dr. de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, Cardior Pharmaceuticals GmbH, NovoNordisk, and Roche; Dr. de Boer received travel support from Abbott, Cardior Pharmaceuticals GmbH, and NovoNordisk. Dr. Kardys received travel reimbursement from Olink and SomaLogic.